Alpine Associates Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Alpine Associates Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-525,550	Closed	-$11.3M	–	74
2025 Q4	$11.3M	Buy	+525,550	New	+$10.2M	0.75%	35

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Alpine Associates Management's AVDL Position: Q1 2026 in Review

Alpine Associates Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 525,550 shares — an estimated $11.3M sold.

Alpine Associates Management first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $11.3M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Alpine Associates Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Alpine Associates Management sold 525,550 Avadel Pharmaceuticals shares in Q1 2026, an estimated $11.3M.
Alpine Associates Management first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Alpine Associates Management's Avadel Pharmaceuticals position peaked at $11.3M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Alpine Associates Management's 13F filing for Q1 2026, filed 21 Apr 2026.